Table 1 Patient and disease characteristics

Number of patients

271

425

Recipient age at SCT (years, range)

53 (18–76)

38 (18–74)

<10⁻⁴

Recipient age (by classes), n (%)

<0.0001

 < 30

46 (17.0 %)

148 (34.8 %)

 30–40

32 (11.8 %)

82 (19.3 %)

 40–50

45 (16.6 %)

98 (23.1 %)

 ≥ 50

148 (54.6 %)

97 (22.8 %)

Recipient gender, n (%)

0.42

 Male

153 (56.5 %)

252 (59.6 %)

 Female

118 (43.5 %)

171 (40.4 %)

Year of SCT (median), year (%)

2010

2011

0.65

 2001–2007

23 (8.5 %)

74 (17.4 %)

<0.0001

 2008–2012

248 (91.5 %)

351 (82.6 %)

Interval from diagnosis to SCT (days, range)

299 (52–3892)

272 (41–3689)

0.24

Donor age

37 years (19–71)

42 years (12–70)

0.83

Donor age (by classes), year (%)

0.55

 < 30

39 (29.3 %)

54 (29.2 %)

 30–40

32 (24.1 %)

33 (17.8 %)

 40–50

29 (21.8 %)

46 (24.9 %)

 ≥ 50

33 (24.8 %)

52 (28.1 %)

Donor gender, n (%)

0.69

 Male

138 (50.9 %)

223 (52.5 %)

 Female

133 (49.1 %)

202 (47.5 %)

Female donor to male recipient, n (%)

76 (28 %)

119 (28.1 %)

0.98

Diagnosis, n (%)

<0.0001

 AML

217 (80.1 %)

286 (67.3 %)

  Good cytogenetics

8 (6 %)

19 (14 %)

  Intermediate cytogenetics

47 (37 %)

53 (39 %)

  Poor cytogenetics

19 (15 %)

18 (13 %)

  Secondary AML

54 (42 %)

45 (33 %)

  Missing cytogenetics

89 (41 %)

151 (53 %)

 ALL

54 (19.9 %)

139 (32.7 %)

  Phi+ ALL

15 (54 %)

27 (36 %)

  Missing cytogenetics

26 (48 %)

64 (46 %)

Disease status at SCT, n (%)

<0.0001

 CR1

78 (28.8 %)

175 (41.2 %)

 ≥ CR2

67 (24.7 %)

118 (27.8 %)

 Active disease

126 (46.5 %)

132 (31.1 %)

Karnosky at SCT, n (%)

0.05

 ≤ 80 %

101 (39.9 %)

109 (32 %)

 > 80 %

152 (60.1 %)

232 (68 %)

 Missing

18 (6.7 %)

84 (19.8 %)

Patient positive CMV serology, n (%)

213 (79.8 %)

311 (78.3 %)

0.66

CMV risk, n (%)

0.06

 Low

35 (13.3 %)

59 (15.2 %)

 Intermediate

169 (64.2 %)

272 (69.3 %)

 High

59 (22.4 %)

56 (14.5 %)